NCT06942182尚未招募2 期
Double Blind Placebo-Controlled Parallel Group Study Of Safety And Efficacy Of Isomyosamine In Treating Sarcopenia After Hip Or Femoral Fracture In Gerontological Population
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 主要终点
- Change in Short Physical Performance Battery (SPPB) Test in subjects treated with Isomyosamine or placebo
研究概览
简要总结
This Phase II clinical study investigates the safety and effectiveness of a new drug, Isomyosamine, in patients with sarcopenia or frailty, conditions associated with aging and muscle weakness. Isomyosamine is a promising oral medication that reduces inflammation by targeting cytokines like TNF-α and IL-6, which are linked to these conditions. Previous studies have shown it is well-tolerated and may help improve muscle strength, mobility, and healing after hip fractures. This trial aims to determine its potential benefits in reducing inflammation and improving recovery in elderly patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 60 to 85 years of age
- •Non-complex, non-comminuted fracture of the femoral head, femoral neck, or acetabulum due to an accidental (non-neurologic or cardiovascular) fall
- •Concomitant medication limited to treatment for chronic conditions
- •The ability to give informed consent and comply with study procedures
- •Body weight ≥35 kg
- •Adequate dietary intake
- •Potential subjects' intention to avoid reproductive activity will be confirmed
- •And one or more of the following criteria:
- •Previous history frailty or sarcopenia diagnosis using standardized tests;
- •Positive assessment for frailty or sarcopenia using standardized tests or as per clinician's judgement;
- •Previous positive assessment for elevated biomarkers of inflammation (serum IL-6 level> LOQ, TNFR1 level > LOQ, and/or TNF-alpha level > LOQ)
排除标准
- •Receiving immunotherapy for cancer or solid organ transplantation
- •Complex or comminuted fracture or fracture of multiple long bones
- •Regular treatment for chronic disease including chronic renal failure, chronic heart failure (CHF) cerebrovascular disease including stroke, rheumatoid arthritis, or polymyalgia rheumatica
- •Chronic kidney disease (estimated glomerular filtration rate [eGFR] <60 mL/min)
- •Newly (< 2 weeks) diagnosed COVID-19
- •Inability or unwillingness to give written informed consent
- •History of upper/lower respiratory tract infection, requiring systemic steroids, antibiotics, and or emergency room (ER) visit or urgent care within 6 weeks of screening visit
- •History of adverse reaction or allergy to TNF inhibitor
- •History of neurological, hepatic, renal, diabetic mellitus, thyroid disorder, psychiatric, addiction or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns per investigator discretion
- •Currently under treatment by an anti-TNFα drug, such as adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and biosimilars
- •Currently under treatment by an anti-diabetic medication, including glucagon-like peptide-1 (GLP-1) drugs such as semaglutide, or any of metformin, jenuvia, or insulin
- •Unwillingness or inability to comply with study procedures, including smoking cessation
- •History of epilepsy or seizure propensity, ataxia, abnormal EEG findings, abnormal brain magnetic resonance image, or other co-morbid neurological conditions
- •Positive TB test
- •Patients who are pregnant or breastfeeding
研究组 & 干预措施
Study Drug: 1000 mg Isomyosamine
Experimental
Subjects randomly assigned to receive 1000 mg Isomyosamine daily via four 250 mg capsules
干预措施: Isomyosamine 250mg (Drug)
Placebo 1000 mg
Placebo Comparator
Subjects randomly assigned to receive 1000 mg placebo daily via four 250 mg capsules
干预措施: Placebo 250 mg (Drug)
结局指标
主要结局
Change in Short Physical Performance Battery (SPPB) Test in subjects treated with Isomyosamine or placebo
时间窗: From enrollment to the end of treatment at 90 days
次要结局
- 4-meter walk test(From enrollment to the end of treatment at 90 days)
- 6-minute walk test(From enrollment to the end of treatment at 90 days)
- Grip strength(From enrollment to the end of treatment at 90 days)
- Effect on serum levels of biochemical markers of TNF activation(From enrollment to the end of treatment at 90 days)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 in the Isomyosamine vs Placebo groups(From enrollment to the end of treatment at 90 days)
研究者
相似试验
Unknown
1 期
A Study of SYHA1805 in Healthy SubjectsHealthy SubjectsNCT04977570CSPC ZhongQi Pharmaceutical Technology Co., Ltd.36
终止
2 期
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney DiseaseGoutChronic Kidney DiseasesHyperuricemiaNCT04987294Allena Pharmaceuticals19
撤回
2 期
Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery PatientsCardiopulmonary BypassHypotensionNCT00482287Meditor Pharmaceuticals Ltd.
Unknown
2 期
Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT03790982Zhejiang Hisun Pharmaceutical Co. Ltd.240
已完成
2 期
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia SyndromeNCT05633407argenx53